The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …

The hallmark of tumorigenesis is the successful circumvention of cell death regulation for
achieving unlimited replication and immortality. Ferroptosis is a newly identified type of cell …

The balance of programmed death-1 (PD-1)-expressing CD8+ T cells and regulatory T
(Treg) cells in the tumor microenvironment (TME) determines the clinical efficacy of PD-1 …

Cancer cells evade T cell-mediated killing through tumour–immune interactions whose
mechanisms are not well understood,. Dendritic cells (DCs), especially type-1 conventional …

The process of epithelial–mesenchymal transition (EMT) is fundamental for embryonic
morphogenesis. Cells undergoing it lose epithelial characteristics and integrity, acquire …

The paradigm of surface-expressed programmed death ligand 1 (PDL1) signalling to
immune cell programmed death 1 (PD1) to inhibit antitumour immunity has helped to …

Cancer immunotherapy has made tremendous clinical progress in advanced-stage
malignancies. However, patients with various tumors exhibit a low response rate to …

Most (if not all) tumors emerge and progress under a strong evolutionary pressure imposed
by trophic, metabolic, immunological, and therapeutic factors. The relative impact of these …

Metastasis is the primary cause of cancer mortality, and cancer frequently metastasizes to
the liver. It is not clear whether liver immune tolerance mechanisms contribute to cancer …

Tumor-associated macrophages (TAMs) represent one of the main tumor-infiltrating immune
cell types and are generally categorized into either of two functionally contrasting subtypes …